The Supreme Court will soon decide a case that could upend the balance built into a bipartisan law that has accelerated the launch of generic drugs and saved American patients, employers, and taxpayers trillions of dollars in recent decades  — while still incentivizing biopharmaceutical companies to research and develop medicines in the first place.

The stakes of the case, Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., extend well beyond the two companies involved. The ruling could have a dramatic effect on incentives to invest in researching additional uses for FDA‑approved medicines.

Recommended Stories

Big government created a drug monopoly. Trump and Congress can fix it

It’s time for Congress to end Big Pharma’s war on generics

For cheap generic drug prices, you can thank 40 years of Hatch-Waxman